drugset / Trial / NCT04083066
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Comparison of the efficacy and safety of rituximab combined with fotemustine, pemetrexed, dexamethasone and rituximab in combination with methotrexate, cytarabine and dexamethasone as first-line regimens in the treatment of primary central nervous system lymphoma
Timeline
- Start
- 2019-09-05
- Primary completion
- 2023-04-01
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 1 g | Intravenous |
| Subject | Methotrexate | Small molecule | 3.5 g | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |